Diabetes Mellitus, Type 1
Conditions
Keywords
MiniMed Paradigm insulin pump, insulin Lispro, Insulin Aspart, Quick-set infusion set
Brief summary
The study is an open-label, randomized, two-period crossover study. Up to one hundred and twenty (120) subjects with type 1 diabetes mellitus (T1DM) who use the MiniMed paradigm insulin pump, who meet the inclusion/exclusion criteria and who provide written Informed Consent will be enrolled in the study. The aim of the study is to examine the safety of the InsuPatch device in a home use setting. Mild Hypoglycemia,hyperglycemia and Adverse events will be compared between two phases of the study : 3 months with the use of the device and 3 months without the use of the device.
Detailed description
The primary objective of this study is to show that safety parameters are similar, when delivering insulin subcutaneously in subjects with type I diabetes using the InsuPatch device along with the Medtronic Minimed Paradigm insulin infusion pump and the Medtronic Minimed Quick-Set® infusion set compared to subcutaneous insulin delivered with the above mentioned equipment, without the InsuPatch device. The participation of each subject in this study will be up to seven months and will include three phases: one week Run in phase , 3 months with device use and 3 months without device use. Study will include 4 clinic visits and bi weekly calls. During the entire study the subjects will be requested to preform at least 5 blood glucose self measurements and record results in a logbook.At each visit blood will be drawn for HBA1C test.
Interventions
DEVICEInsuPatch
Heaters for single use and a permanent control unit.
Sponsors
Insuline Medical Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Subject's age range 18- 65 years old (including 18 and 65 years old) 2. BMI: 18-35 kg/m2 3. Type 1 diabetes patients using a MiniMed Paradigm insulin pump for at least six months, who are administering insulin Lispro or Insulin Aspart and are using the Quick-set infusion set. 4. Patients with T1DM whose HbA1c values are at or below 9.5% (including 9.5%) and at or above 6% (including 6%). 5. Agree to sign consent form before any study-specific tests or procedures are to be performed. 6. Subject's completed at least 14 measurements during the Run-In Phase and readiness to continue the study with at least 5 blood glucose recordings per day and keep a logbook during the study period. 7. Subject readiness to use the InsuPatch, his comprehension of the study requirements and treatment procedures. 8. Willingness to comply with all specified follow-up evaluations.
Exclusion criteria
1. Pregnancy 2. Breast feeding women. 3. Alcohol addiction 4. CABG (Coronary Artery Bypass Graft), MI (Myocardial Infarction) or active Ischemic Heart Disease prior to study date. 5. CVA (cardiovascular accident) or TIA (transient ischemic accident) events prior to study date. 6. Uncontrolled hypertension (blood pressure in mm HG \>160 systolic or \> 95 diastolic) . 7. Any history of gastroparesis or enteroparesis. 8. Abnormal kidney and/ or liver function tests. (Defined as Creatinine \>1.5 mg/dL, liver tests\> 2 times the upper limit of normal). 9. A severe hypoglycemic event requiring a glucagon injection or intravenous glucose infusion within the last six months prior to study inclusion. 10. Hypoglycemia unawareness. 11. Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior to study inclusion. 12. Psychological incompetence. 13. Signs of drug abuse. 14. Any other clinical condition or history, which seems to be relevant for the Principle Investigator to disqualify a participant. 15. Subjects with diminished skin integrity, Excessive fibrosis, lipo-hypertrophy or eczema at infusion sites. 16. Heat sensitive subjects. 17. Subjects involved in or planning to participate in other studies. 18. Subjects using any drug therapy, other than insulin, to control their blood glucose levels.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without. | safety will be assesed after 6 months at the study completion | The confirmatory safety endpoint is, for each subject, frequency of mild hypoglycemia events (Blood Glucose\<60mg/dl) with InsuPatch and without. The number of events will be assessed from subject logbook and will be compared between two arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of hyperglycemic events (BG>300 mg/dl, Fasting BG>250 mg/dl) with InsuPatch and without. | safety will be assesed after 6 months at the study completion | Frequency of hyperglycemic events (BG\>300 mg/dl, Fasting BG\>250 mg/dl) with InsuPatch and without.The number of events will be assesed from subject logbook and will be compared between two arms. |
| Adverse events (AE's) count with InsuPatch and without. | safety will be assesed after 6 months at the study completion | Adverse events (AE's) whether or not deemed related to study device with InsuPatch and without.The number of events will be assesed dering the subject visits and bi-weekly calls and will be compared between two arms. |
Countries
Israel, United States
Outcome results
None listed